Literature DB >> 16314476

Massive apoptosis in lymphoid organs in animal models for primary and secondary progressive multiple sclerosis.

Ikuo Tsunoda1, Jane E Libbey, Li-Qing Kuang, Emily Jane Terry, Robert S Fujinami.   

Abstract

The mechanism(s) responsible for generating the different forms of multiple sclerosis, primary progressive (PP) and secondary progressive (SP) versus relapsing-remitting (RR), is not well understood. Using myelin oligodendrocyte glycoprotein (MOG)(92-106), we have established animal models that mimic the different types of multiple sclerosis. A.SW mice develop PP or SP-experimental allergic encephalomyelitis (EAE) with large areas of demyelination and high titers of MOG antibody whereas SJL/J mice develop RR-EAE with perivascular T cells and mild demyelination. In A.SW progressive EAE, we found atrophy of the thymus, spleen, and lymph nodes with depletion of T and B cells and massive apoptosis, as demonstrated by immunohistochemistry, terminal dUTP nick-end labeling, and DNA agarose gel electrophoresis. To test whether lymphoid apoptosis itself contributes to disease progression, we injected SJL/J mice with apoptotic thymocytes. Injection of apoptotic cells resulted in greater than 20% of mice developing SP-EAE with ataxia. SJL/J mice with SP-EAE had large areas of demyelination, high MOG antibody titers and atrophic lymphoid organs. Spleen cells from mice with progressive EAE produced less interferon-gamma than those from RR-EAE when stimulated with mitogen. We suggest that induction of lymphoid apoptosis alters the balance of Th1 versus Th2 immune responses and increases MOG antibody production, leading to exacerbation of demyelination and subsequent disease progression.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16314476      PMCID: PMC1613181          DOI: 10.1016/S0002-9440(10)61247-3

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  78 in total

1.  A receptor for phosphatidylserine-specific clearance of apoptotic cells.

Authors:  V A Fadok; D L Bratton; D M Rose; A Pearson; R A Ezekewitz; P M Henson
Journal:  Nature       Date:  2000-05-04       Impact factor: 49.962

Review 2.  Mast cells: new targets for multiple sclerosis therapy?

Authors:  Jacques P Zappulla; Michel Arock; Lennart T Mars; Roland S Liblau
Journal:  J Neuroimmunol       Date:  2002-10       Impact factor: 3.478

3.  1H MRSI comparison of white matter and lesions in primary progressive and relapsing-remitting MS.

Authors:  J Suhy; W D Rooney; D E Goodkin; A A Capizzano; B J Soher; A A Maudsley; E Waubant; P B Andersson; M W Weiner
Journal:  Mult Scler       Date:  2000-06       Impact factor: 6.312

Review 4.  Immunopathogenic and clinical relevance of antibodies against myelin oligodendrocyte glycoprotein (MOG) in Multiple Sclerosis.

Authors:  T Berger; M Reindl
Journal:  J Neural Transm Suppl       Date:  2000

5.  Genetic and epigenetic influence on EAE phenotypes induced with different encephalitogenic peptides.

Authors:  R A Sobel
Journal:  J Neuroimmunol       Date:  2000-08-01       Impact factor: 3.478

6.  Transcriptional and translational regulation of inflammatory mediator production by endogenous TGF-beta in macrophages that have ingested apoptotic cells.

Authors:  P P McDonald; V A Fadok; D Bratton; P M Henson
Journal:  J Immunol       Date:  1999-12-01       Impact factor: 5.422

Review 7.  Apoptosis in sepsis: a new target for therapeutic exploration.

Authors:  C Oberholzer; A Oberholzer; M Clare-Salzler; L L Moldawer
Journal:  FASEB J       Date:  2001-04       Impact factor: 5.191

8.  Antibody association with a novel model for primary progressive multiple sclerosis: induction of relapsing-remitting and progressive forms of EAE in H2s mouse strains.

Authors:  I Tsunoda; L Q Kuang; D J Theil; R S Fujinami
Journal:  Brain Pathol       Date:  2000-07       Impact factor: 6.508

9.  A neuropathological analysis of experimental autoimmune encephalomyelitis with predominant brain stem and cerebellar involvement and differences between active and passive induction.

Authors:  D M Muller; M P Pender; J M Greer
Journal:  Acta Neuropathol       Date:  2000-08       Impact factor: 17.088

10.  Butyrophilin, a milk protein, modulates the encephalitogenic T cell response to myelin oligodendrocyte glycoprotein in experimental autoimmune encephalomyelitis.

Authors:  A Stefferl; A Schubart; M Storch2; A Amini; I Mather; H Lassmann; C Linington
Journal:  J Immunol       Date:  2000-09-01       Impact factor: 5.422

View more
  21 in total

1.  MP4- and MOG:35-55-induced EAE in C57BL/6 mice differentially targets brain, spinal cord and cerebellum.

Authors:  Stefanie Kuerten; Dilyana A Kostova-Bales; Lukas P Frenzel; Justine T Tigno; Magdalena Tary-Lehmann; Doychin N Angelov; Paul V Lehmann
Journal:  J Neuroimmunol       Date:  2007-07-25       Impact factor: 3.478

2.  Th17-biased RORγt transgenic mice become susceptible to a viral model for multiple sclerosis.

Authors:  Nicholas E Martinez; Fumitaka Sato; Eiichiro Kawai; Seiichi Omura; Satoru Takahashi; Keigyou Yoh; Ikuo Tsunoda
Journal:  Brain Behav Immun       Date:  2014-07-18       Impact factor: 7.217

Review 3.  Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS).

Authors:  Cris S Constantinescu; Nasr Farooqi; Kate O'Brien; Bruno Gran
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

4.  Immunopathological patterns from EAE and Theiler's virus infection: Is multiple sclerosis a homogenous 1-stage or heterogenous 2-stage disease?

Authors:  Nicholas E Martinez; Fumitaka Sato; Seiichi Omura; Alireza Minagar; J Steven Alexander; Ikuo Tsunoda
Journal:  Pathophysiology       Date:  2012-05-26

Review 5.  Experimental autoimmune encephalomyelitis as a testing paradigm for adjuvants and vaccines.

Authors:  Jane E Libbey; Robert S Fujinami
Journal:  Vaccine       Date:  2010-09-16       Impact factor: 3.641

6.  Axonal degeneration as a self-destructive defense mechanism against neurotropic virus infection.

Authors:  Ikuo Tsunoda
Journal:  Future Virol       Date:  2008       Impact factor: 1.831

7.  Diazoxide attenuates autoimmune encephalomyelitis and modulates lymphocyte proliferation and dendritic cell functionality.

Authors:  N Virgili; P Mancera; C Chanvillard; A Wegner; B Wappenhans; M J Rodríguez; C Infante-Duarte; J F Espinosa-Parrilla; M Pugliese
Journal:  J Neuroimmune Pharmacol       Date:  2014-06-18       Impact factor: 4.147

8.  Regulatory role of CD1d in neurotropic virus infection.

Authors:  Ikuo Tsunoda; Tomoko Tanaka; Robert S Fujinami
Journal:  J Virol       Date:  2008-08-06       Impact factor: 5.103

Review 9.  Neuropathogenesis of Theiler's murine encephalomyelitis virus infection, an animal model for multiple sclerosis.

Authors:  Ikuo Tsunoda; Robert S Fujinami
Journal:  J Neuroimmune Pharmacol       Date:  2009-11-06       Impact factor: 4.147

10.  Contrasting roles for Valpha14+ natural killer T cells in a viral model for multiple sclerosis.

Authors:  Ikuo Tsunoda; Tomoko Tanaka; Masaru Taniguchi; Robert S Fujinami
Journal:  J Neurovirol       Date:  2008-12-27       Impact factor: 2.643

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.